Early trial aims to zap advanced prostate cancer with targeted radiation and chemo
NCT ID NCT07316686
Summary
This early-stage study is testing the safety of combining a standard chemotherapy drug (docetaxel) with a newer targeted radiation drug (Lutetium-PSMA) for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy. The main goal is to find the safest and most effective dose of the chemotherapy to use alongside the radiation drug. Researchers will enroll about 18 men who have not yet had chemotherapy for this advanced stage of their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto do Câncer do Estado de São Paulo - ICESP
São Paulo, São Paulo, 01246000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.